1191 related articles for article (PubMed ID: 19020749)
1. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
2. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
3. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
[TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
6. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
8. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
11. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
12. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
[TBL] [Abstract][Full Text] [Related]
13. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
Cunningham MP; Thomas H; Fan Z; Modjtahedi H
Cancer Res; 2006 Aug; 66(15):7708-15. PubMed ID: 16885373
[TBL] [Abstract][Full Text] [Related]
14. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
15. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
17. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
18. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
20. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
